ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

September 28, 2018

The ASCO Research Community Forum (RCF) 2018 Annual Meeting brought together 159 physician investigators and research staff from 34 states across the country—its largest meeting to-date—to discuss contemporary challenges and develop creative solutions in conducting and managing clinical trials. The meeting, held annually at ASCO's headquarters in the Washington DC Metro area, spanned two days from September 23-24, with a theme of Innovative Solutions. Best Practices. Excellence in Cancer Research.

September 28, 2018

In a comment letter from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, to the Food and Drug Administration (FDA) Commissioner Scott Gottlieb, the society expressed appreciation for FDA’s efforts to gather stakeholder perspectives on enhancing access to biologic cancer therapies and ensuring greater availability of biosimilars, while retaining a balance between innovation and competition.

September 27, 2018

On September 27, 2018, the Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

September 26, 2018

More than 100 ASCO volunteers from across the country came to Capitol Hill on September 25-26 for the 2018 ASCO Advocacy Summit, where they urged Congress to act on major policy priorities to support cancer research and ensure access to high-quality care for the millions of people in the United States with cancer.

September 26, 2018

ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.

September 25, 2018

In a comment letter to the Centers for Medicare & Medicaid Services (CMS) ASCO expressed significant concerns that provisions in the 2019 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule would undermine Medicare beneficiary access to cancer care due to reimbursement cuts based on site-of-service that fail to address systemic payment deficiencies for cancer care services under Medicare. ASCO urges CMS to forego implementing any additional utilization management strategies and instead enhance patient access to cancer care by facilitating participation in Advanced Alternative Payment Models (APMs) that use oncology clinical pathways to promote high-quality cancer care. 

September 25, 2018

The American Society of Clinical Oncology presented Representative Kevin Yoder (KS-03) with the 2018 Congressional Leadership Award today. Each year, ASCO presents this Award to a Member of Congress who has continuously supported legislation that promotes an improved practice environment for the oncology community and improves the quality of care for cancer patients

September 25, 2018

The American Society of Clinical Oncology (ASCO) presented its 2017 Advocate of the Year Award to Ray D. Page, DO, PhD, FACOI, for his exceptional  advocacy efforts on behalf of individuals living with cancer and their cancer care teams. As a member of the Government Relations Committee and in other roles, Dr. Page has provided distinguished leadership in the society’s policy and advocacy efforts.

September 24, 2018

ASCO is now holding Quality Training Program seminars outside of the U.S. for practices interested in participating.

September 24, 2018

On September 24, 2018, the Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In addition, duvelisib received accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

September 20, 2018

Last week, the Food and Drug Administration (FDA) announced a series of critical enforcement actions related to the sale and marketing of e-cigarettes to children and young adults. With the use of e-cigarettes among youth growing at an alarming rate in recent years, the agency has taken record actions to address this challenge and protect youth from the dangers of tobacco products through its Youth Tobacco Prevention Plan.

September 18, 2018

In the latest ASCO in Action Podcast, Manali Patel, MD, MPH, joined ASCO CEO Dr. Clifford A. Hudis to discuss ASCO’s position statement on Medicaid work requirements, which addresses state waivers submitted to the Centers for Medicare & Medicaid Services (CMS) that, if approved, would make Medicaid eligibility, continued coverage, cost-sharing, and other program benefits dependent on a beneficiary’s work status. 

September 18, 2018

More than 100 oncology care providers from across the United States are heading to Capitol Hill September 25 – 26 to participate in the 2018 ASCO Advocacy Summit. Advocates will meet with Members of Congress and their staff to educate them on critical issues affecting individuals with cancer and their providers, and to encourage lawmakers to support cancer policies that will ensure access to high-quality, high-value cancer care.

September 18, 2018

ASCO recently hosted a webinar offering an overview of the 2019 Medicare Physician Fee Schedule and Quality Payment Program proposed rule and its potential impact on individuals with cancer. ASCO strongly opposes aspects of the proposed rule that could significantly cut cancer care resources needed to provide high-quality care, and the society urges the Centers for Medicare & Medicaid Services (CMS) to abandon the proposal. ASCO members can still watch this important webinar and view the slides from the presentation.

September 13, 2018

A new study in the Journal of Oncology Practice surveys practices within ASCO’s Quality Oncology Practice Initiative (QOPI®) to learn about real world implementation and use of Patient Reported Outcomes (PROs). The survey yielded valuable information on the perception of PROs among oncology practices and the data currently being collected.

Pages